Active site binding modes of HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 43, Issue 22, 2000, Pages 4109-4117

  Sotriffer, C A ^a   Ni, H ^a   McCammon, J A ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLOROINDOL 3 YL) 3 (TETRAZOLYL) 1,3 PROPANEDIONE ENOL; 3,3,3',3' TETRAMETHYL 1,1' SPIROBIS(INDAN) 5,5',6,6' TETROL; 4 ACETYLAMINO 5 HYDROXYNAPHTHALENE 2,7 DISULFONIC ACID; CICHORIC ACID; INTEGRASE INHIBITOR; QUINALIZARIN; UNCLASSIFIED DRUG; Y 3;

ARTICLE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; STRUCTURE ANALYSIS;

ANTHRAQUINONES; CAFFEIC ACIDS; CATALYTIC DOMAIN; CATECHOLS; DRUG DESIGN; HIV INTEGRASE INHIBITORS; HIV-1; INDOLES; LIGANDS; MODELS, MOLECULAR; NAPHTHALENESULFONATES; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES; TETRAZOLES;

EID: 0034597625     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000194t     Document Type: Article

References (42)

1. The retroviral enzymes
2. HIV cDNA integration: Molecular biology and inhibitor development
3. Molecular mechanisms in retrovirus DNA integration
4. Inhibitors of human immunodeficiency virus integrase
5. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching
6. Discovery of HIV-1 integrase inhibitors by pharmacophore searching
7. Depsides and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching
8. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore
9. Methods for including the dynamic fluctuations of a protein in computer-aided drug design
10. Developing a dynamic pharmacophore model for HIV-1 integrase
11. Technique for developing a pharmacophore model that accommodates inherent protein flexibility: An application to HIV-1 integrase
12. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design
13. HIV-1 integrase inhibitor interactions at the active site: Prediction of binding modes unaffected by crystal packing
14. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function
15. Ligand - Protein docking and rational drug design
16. Modeling protein - Ligand complexes
17. Computational methods for biomolecular docking
18. Current issues in de novo molecular design
19. Recent advances in ligand design methods
20. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase targeted inhibitor
21. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules
22. Human immunodeficiency virus type 1 cDNA integration: New aromatic hydroxylated inhibitors and studies of the inhibition mechanism
23. A new class of HIV-1 integrase inhibitors. The 3,3,3',3'-tetramethyl-1,1'-spirobis(indan)-5,5',6,6'-tetrol family
24. Iterative partial equilization of orbital electronegativity - A rapid access to atomic charges
25. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium
26. Molecular dynamics studies on the HIV-1 integrase catalytic domain
27. A new force field for molecular mechanical simulations of nucleic acids and proteins
28. Automated docking of substrates to proteins by simulated annealing
29. Distributed automated docking of flexible ligands to proteins: Parallel applications of AuteDock 2.4
30. Automated docking of flexible ligands: Applications of AutoDock
31. Comparative docking studies on ligand binding to the multispecific antibodies IgE-La2 and IgE-Lb4
32. Automated docking of ligands to antibodies: Methods and applications
33. Dicaffeoylquinic and dicaffeoyltartaric acid are selective inhibitors of human immunodeficiency virus type 1 integrase
34. Chicoric acid analogues as HIV-1 integrase inhibitors
35. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases
36. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids
37. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase
38. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity
39. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photocrosslinking
40. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction
41. Identification of a nucleotide binding site in HIV-1 integrase